<DOC>
	<DOCNO>NCT01804400</DOCNO>
	<brief_summary>This study ass safety efficacy QAW039 alone combination Montelukast patient allergic rhinitis ( hay fever ) use environmental exposure chamber .</brief_summary>
	<brief_title>A Clinical Trial Test How Well Two Drugs , QAW039 Montelukast Work Both Individually Together , Target Allergic Rhinitis Using Environmental Exposure Chamber</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<criteria>Male female age 1865 year inclusive , clinical history intermittent allergic rhinitis seasonal onset offset nasal allergy symptom last two grass pollen allergy season . A positive skin prick test Visit 1 dactylis glomerata wheal diameter equal great 3 mm negative control wheal diameter zero . A positive skin prick test within 12 month prior Visit 1 also acceptable . FEV1 measure spirometry must ≥80 % predicted value screening . If patient achieve ≥80 % predict value may repeat prior EEC challenge visit 2 . TNSS score ≥6 least one assessment 2h EEC challenge Screening . Use investigational drug time enrollment , within 30 day 5 halflives enrollment , whichever longer ; longer require local regulation , limitation participation investigational trial base local regulation . Pregnant nursing ( lactate ) woman , Women childbearing potential , defined woman physiologically capable become pregnant , unless use effective method contraception dose study treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>